{"id":390142,"date":"2020-11-20T00:00:00","date_gmt":"2020-11-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0004-2020-biopharma-malignant-melanoma-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-04-27T23:36:39","modified_gmt":"2026-04-27T23:36:39","slug":"dlsfon0004-2020-biopharma-malignant-melanoma-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0004-2020-biopharma-malignant-melanoma-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Malignant Melanoma | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck &#038; Co.) and Opdivo \u00b1 Yervoy (Bristol Myers Squibb), as well as BRAF\/MEK inhibitor combination regimens, such as Roche \/ Genentech\u2019s Zelboraf + Cotellic, Novartis\u2019s Tafinlar + Mekinist, and, more recently, Pfizer \/ Array BioPharma\u2019s Braftovi + Mektovi, has significantly changed the treatment landscape for malignant melanoma in both the resectable and metastatic settings. Nonetheless, opportunities remain for novel agents specifically targeting the underpenetrated <em>BRAF<\/em> wild-type unresectable or metastatic population. With the expected introduction of novel agents and combination regimens, the malignant melanoma treatment algorithm will continue to evolve. In such a dynamic indication, marketed drugs need to be carefully positioned to achieve optimal uptake.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>How large are the clinically and commercially relevant malignant melanoma drug-treatable populations? Will drug-treatment rates increase over the forecast period?<\/li>\n<li>What is the current treatment landscape in malignant melanoma? Which currently approved drugs are the most important and why?<\/li>\n<li>Which drugs in late-phase development are poised to change the treatment landscape for malignant melanoma and how? What sales\/uptake could these drugs secure in the malignant melanoma market?<\/li>\n<li>What are the key drivers and constraints in the malignant melanoma market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content Highlights<\/strong><\/p>\n<p>Geographies: United States, EU5, Japan.<\/p>\n<p>Primary research: 20 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other DRG research.<\/p>\n<p>Epidemiology: Diagnosed incidence of malignant melanoma by country, segmented by disease stage and <em>BRAF<\/em> mutation status.<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key malignant melanoma therapies through 2029, segmented by brands\/generics and epidemiological subpopulations.<\/p>\n<p>Emerging therapies: Phase III: 9 drugs; Phase II: 11 drugs; coverage of select preclinical and Phase I products.<\/p>\n<p><strong>Product Description <\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390142","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-malignant-melanoma","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390142\/revisions"}],"predecessor-version":[{"id":576476,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390142\/revisions\/576476"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}